tiprankstipranks
Trending News
More News >
Zhongchao Inc (ZCMD)
:ZCMD
US Market
Advertisement

Zhongchao (ZCMD) AI Stock Analysis

Compare
54 Followers

Top Page

ZCMD

Zhongchao

(NASDAQ:ZCMD)

Select Model
Select Model
Select Model
Neutral 43 (OpenAI - 4o)
Rating:43Neutral
Price Target:
Zhongchao's overall stock score is low primarily due to significant financial struggles, including negative cash flows and net losses. Technical analysis indicates a bearish trend, further weighing on the stock. Valuation metrics are also unfavorable, with a negative P/E ratio and no dividend yield, suggesting limited investor appeal at present.

Zhongchao (ZCMD) vs. SPDR S&P 500 ETF (SPY)

Zhongchao Business Overview & Revenue Model

Company DescriptionZhongchao Inc. provides healthcare information, education, and training services in the People's Republic of China. The company offers online and onsite health information services, healthcare education programs, and healthcare training products, including clinical practice training, open classes of popular medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content. It also provides customized medical courses and medical training services; and patient management services through online platform under the Zhongxun brand. The company operates through its mdmooc.org online platform under the MDMOOC brand; and Sunshine Health Forums, a Wechat subscription account and mobile app. It serves enterprises, non-for-profit organizations, and medical journals, as well as healthcare professionals, nurses, doctors, and other healthcare workers. The company was founded in 2012 and is headquartered in Shanghai, China.
How the Company Makes MoneyZhongchao Inc. generates revenue primarily through its Medical Training and Education segment by offering training programs to healthcare professionals, which include online courses, workshops, and seminars. These programs are often developed in collaboration with medical institutions and professional organizations, providing tailored educational content that meets industry standards and requirements. Additionally, the company monetizes its Internet-Based Healthcare Information Platforms through advertising, subscriptions, and partnerships with pharmaceutical companies and healthcare organizations that wish to reach their target audiences via Zhongchao's platforms. Revenue is further bolstered through collaborations with governmental and non-governmental organizations that seek Zhongchao's expertise in healthcare education and information dissemination.

Zhongchao Financial Statement Overview

Summary
Zhongchao faces financial challenges with declining revenues, consistent net losses, and negative cash flows. While the balance sheet shows a strong equity position and low leverage, the company's operational inefficiencies and liquidity issues raise concerns about its long-term sustainability.
Income Statement
40
Negative
Zhongchao's income statement reveals a decline in total revenue from the previous year and negative net income, indicating financial difficulties. The gross profit margin stands at 56.2%, showing efficiency in managing production costs. However, the negative EBIT and net profit margins reflect operational inefficiencies and persistent losses.
Balance Sheet
55
Neutral
The balance sheet indicates a strong equity position with an equity ratio of 80.5%, suggesting financial stability and low leverage, as evidenced by a minimal debt-to-equity ratio of 0.003. However, the return on equity is negative due to persistent losses, highlighting challenges in generating returns for shareholders.
Cash Flow
30
Negative
The cash flow statements show negative free cash flow and operating cash flow, indicating liquidity challenges. The significant decline in free cash flow from the previous year underscores the company's struggles to generate cash from operations, posing risks for future financial flexibility.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue13.12M15.86M19.43M14.15M16.30M17.99M
Gross Profit6.88M8.91M8.51M6.36M9.44M11.87M
EBITDA-406.67K87.95K-4.49M-2.22M-2.32K4.67M
Net Income-1.70M-643.23K-11.34M-2.94M238.66K4.46M
Balance Sheet
Total Assets26.31M25.88M24.42M38.61M36.27M34.82M
Cash, Cash Equivalents and Short-Term Investments15.03M13.08M13.45M12.04M14.21M17.11M
Total Debt27.59K57.52K808.16K1.70M201.56K62.16K
Total Liabilities2.56M1.73M3.38M5.60M3.70M2.98M
Stockholders Equity20.27M20.84M18.01M29.93M32.57M31.83M
Cash Flow
Free Cash Flow-1.41M-4.52M-785.51K-2.52M1.06M-1.89M
Operating Cash Flow-461.96K-1.47M54.23K-661.74K2.86M-1.04M
Investing Cash Flow-990.36K-1.81M-3.75M-3.35M-4.02M-4.09M
Financing Cash Flow3.84M3.84M0.001.85M0.0011.50M

Zhongchao Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.25
Price Trends
50DMA
1.04
Positive
100DMA
1.10
Positive
200DMA
1.25
Positive
Market Momentum
MACD
0.04
Negative
RSI
64.90
Neutral
STOCH
73.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZCMD, the sentiment is Positive. The current price of 1.25 is above the 20-day moving average (MA) of 1.13, above the 50-day MA of 1.04, and above the 200-day MA of 1.25, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 64.90 is Neutral, neither overbought nor oversold. The STOCH value of 73.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZCMD.

Zhongchao Risk Analysis

Zhongchao disclosed 77 risk factors in its most recent earnings report. Zhongchao reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
If the PRC operating entities fail to submit their annual reports to SAMR in a timely manner or at all, the PRC operating entities may be recorded in the list of abnormal business operation, which have adverse impact on our business operations. Q4, 2022
2.
Failure to comply with PRC regulations in relation to lease property may subject us to penalty Q4, 2022
3.
Uncertainties regarding the enforcement of laws, and changes in policies, laws and regulations could materially and adversely affect us. Q4, 2022

Zhongchao Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
51
Neutral
-14.88%54.76%
43
Neutral
$31.57M-8.96%-24.64%92.19%
40
Underperform
$17.97M-44.11%-97.11%89.02%
38
Underperform
$10.48M-3190.66%-280.85%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ZCMD
Zhongchao
1.25
-0.98
-43.95%
STRM
Streamline Health Solutions
5.33
3.13
142.27%
SCNX
Scienture Holdings
0.87
-6.12
-87.55%
ONMD
OneMedNet
1.03
0.37
56.06%
VSEE
VSee Health
0.64
-0.57
-47.11%
MGRX
Mangoceuticals, Inc.
2.27
-0.99
-30.37%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 30, 2025